Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis-Reference-Cited by-同舟云学术

Nilotinib first-line therapy in patients with Philadelphia chromosome-negative/BCR-ABL-positive chronic myeloid leukemia in chronic phase: ENEST1st sub-analysis

Published:2017-02-21 Issue:7 Volume:143 Page:1225-1233
ISSN:0171-5216
Container-title:Journal of Cancer Research and Clinical Oncology
language:en
Short-container-title:J Cancer Res Clin Oncol

Author:

Hochhaus Andreas,Mahon Franҫois-Xavier,le Coutre Philipp,Petrov Ljubomir,Janssen Jeroen J. W. M.,Cross Nicholas C. P.,Rea Delphine,Castagnetti Fausto,Hellmann Andrzej,Rosti Gianantonio,Gattermann Norbert,Coronel Maria Liz Paciello,Gutierrez Maria Asuncion Echeveste,Garcia-Gutierrez Valentin,Vincenzi Beatrice,Dezzani Luca,Giles Francis J.

Funder

Novartis Pharma

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Link

http://link.springer.com/article/10.1007/s00432-017-2359-9/fulltext.html

Reference33 articles.

1. Baccarani M et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884. doi: 10.1182/blood-2013-05-501569

2. Bartram CR (1985) bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia. J Exp Med 162:2175–2179

3. Bartram CR et al (1983) Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 306:277–280